Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines.
Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world including DORYX®, KAPANOL®, ERYC®, ASTRIX® and LOZANOC®/TOLSURA®.
Mayne Pharma also in-licenses novel medicines from around the world. Through innovation and collaborative partnerships, out products address unmet clinical needs. We are proud to support the areas of women’s health, dermatology and infectious disease.
Our product portfolio:
Click here for further information on: